Clinical and laboratory features of Mycobacterium mageritense.
Six clinical isolates of the nonpigmented, rapidly growing species Mycobacterium mageritense were recovered from sputum, bronchial wash, blood, sinus drainage, and two surgical wound infections from separate patients in Texas, New York, Louisiana, and Florida. The isolates matched the ATCC type strain by PCR restriction enzyme analysis of the 65-kDa hsp gene sequence of Telenti, high-performance liquid chromatography, biochemical reactions, and partial 16S rRNA gene sequencing. These are the first isolates of this species to be described in the United States and the first isolates to be associated with clinical disease. Susceptibility testing of all known isolates of the species revealed all isolates to be susceptible or intermediate to amikacin, cefoxitin, imipenem, and the fluoroquinolones and sulfonamides but resistant to clarithromycin. Because of their phenotypic and clinical similarity to isolates of the Mycobacterium fortuitum third biovariant complex (sorbitol positive), isolates of M. mageritense are likely to go undetected unless selected carbohydrate utilization or molecular identification methods are used.
Wallace
Richard J
RJ
Department of Microbiology, University of Texas Health Center, Tyler 75708, USA. Richard.Wallace@uthct.edu
Brown-Elliott
Barbara A
BA
Hall
Leslie
L
Roberts
Glenn
G
Wilson
Rebecca W
RW
Mann
Linda B
LB
Crist
Christopher J
CJ
Chiu
Sher H
SH
Dunlap
Robbie
R
Garcia
Maria J
MJ
Bagwell
J Todd
JT
Jost
Kenneth C
KC
D000328:Adult; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001426:Bacterial Proteins / Q000235:genetics; D015373:Bacterial Typing Techniques; D050260:Carbohydrate Metabolism; D002851:Chromatography, High Pressure Liquid; D004275:DNA, Ribosomal / Q000032:analysis; D005260:Female; D006360:Heat-Shock Proteins / Q000235:genetics; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D009161:Mycobacterium / Q000145:classification* / Q000187:drug effects / Q000235:genetics / Q000472:pathogenicity; D009164:Mycobacterium Infections / Q000175:diagnosis* / Q000382:microbiology / Q000503:physiopathology; D012336:RNA, Ribosomal, 16S / Q000235:genetics; D015183:Restriction Mapping; D017422:Sequence Analysis, DNA
D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D004275:DNA, Ribosomal; D006360:Heat-Shock Proteins; D012336:RNA, Ribosomal, 16S